The Chinese Proteomics Team Launched π-HuB Project to the Global Community at HUPO 2022 Conference








The HUPO 2022 conference, which took place in Cancun, Mexico from December 4th to 8th, marks the first offline conference held by the Human Proteome Organization (HUPO) since the outbreak of the COVID-19 pandemic three years ago, and also the first HUPO conference ever held in Latin America. Despite the challenges posed by the pandemic, the event managed to bring together nearly a thousand experts and scholars from 36 countries and regions around the world. This conference involves over 45 invited speeches, 74 special reports, and more than 500 posters, offering a much-needed opportunity for scientists to meet face-to-face and exchange ideas.

Led by Professor Fuchu He, China's delegation attended the conference and conducted a series of promotional activities for the Proteomic Navigater of the Human Body Project (π-HuB Project), which received very enthusiastic responses from the attendees.

On December 7th, China's delegation organized a global press release for the π-HuB project, along with a seminar where they introduced its scientific goals, technical strategies, organizational plans, and construction objectives to audience. They also encouraged global teams to join the program to strengthen their collaboration.

On December 8th, Professor He was invited to explain the unique concept of the π-HuB project and its complementarity with existing proteomics programs, which helped attendees understand the project better. Scientists involved in this conference expressed their anticipation for the launch of the π-HuB program and their desire to join it, stating that its release was the biggest highlight of the HUPO conference.


You are applying

Laboratory staff of biological mass spectrometry platform

Full Name*


Resume uploading

The size cannot exceed 5M and supports word, pdf, and html


Our page uses cookies

We use cookies to personalize and enhance your browsing experience on our website. By clicking "Accept All", you agree to use cookies. You can read our Cookie Policy for more information.